Articles tagged with Antibodies
Researchers at Boston Children's Hospital have identified a mechanism for immune cells to recycle defective or autoreactive antibodies by editing their genes. The new process uses an enzyme called RAG to swap out light chains with nearby new ones, often making them non-defective and functional.
Researchers at Scripps Research create a nanodisc platform that preserves key parts of viral surface proteins, allowing for better understanding of antibody interactions. This approach can be applied to other viruses with similar membrane-embedded proteins, such as influenza and SARS-CoV-2.
Researchers have mapped the molecular mechanism behind allergic reactions and developed tailored antibodies to block life-threatening responses. The findings suggest a new approach to targeting the most important allergens and provide a starting point for developing more precise treatments for severe allergy.
Researchers at Karolinska Institutet have mapped immune gene variation across multiple global populations, identifying common genetic variants that affect antibody production. The findings may contribute to understanding infection susceptibility and inform vaccine design.
Researchers at Cold Spring Harbor Laboratory found that antibodies produced in response to cancer can attack the brain, causing autoimmune diseases like lupus and multiple sclerosis. The study suggests that these antibodies may be harnessed to develop new treatments for triple-negative breast cancer.
A new study suggests that autoantibodies from Long COVID patients can induce persistent pain-like symptoms in mice, providing evidence for a potential causal role of autoantibodies in the condition. The research also highlights distinct biological subgroups and offers hope for targeted antibody-based therapies.
Researchers reveal that skin-cell calcium channel TRPV3 is activated by plant-derived fragrant molecules, leading to enhanced immune responses and potential new vaccine adjuvants. The study provides a novel understanding of immune crosstalk and offers a safer approach to enhancing vaccine efficacy.
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
Rice bioengineer Omid Veiseh has been awarded a $2.2 million grant to develop implantable cell factory platforms that can deliver therapeutic antibodies over extended periods. The platform aims to reduce dosing frequency and improve access to biologic therapies in low- and middle-income countries.
Researchers discovered Marburg virus enters human cells up to 300 times more efficiently than Ebola, thanks to its unique entry protein. A nanobody has been identified to block its attachment to the receptor, providing a potential therapeutic strategy.
Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.
Researchers have identified three new proteins, called epitopes, that help the body determine 'safe' foods, aiding in food tolerance and allergy understanding. The epitopes were found in seed proteins from corn, wheat, and soybean, and interact with regulatory T cells to inform tolerance-or-rejection decisions.
A randomized, double-blind clinical trial found that a natural fungal supplement, FoTv, reduced short-term vaccine side effects and helped antibodies last longer in people who had not previously been exposed to COVID-19. The study suggests that FoTv may help strengthen vaccine protection without increasing side effects.
Researchers at Fred Hutchinson Cancer Center developed new genetically human monoclonal antibodies that prevent EBV from infecting immune cells. The study highlights one of the antibodies that successfully blocked infection in mice with human immune systems.
Researchers developed an AI-driven pipeline to create functional intracellular antibodies, overcoming major barriers in intrabody development. The approach successfully redesigned structures compatible within the cellular environment, enabling high target specificity and stability.
A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...
A novel viral vector, AAVT42, efficiently delivers therapeutic genes to the brain, restoring memory and protecting neuronal structures in multiple models of Alzheimer's disease. BDNF treatment achieves significant cognitive rescue, facilitating structural repair and suppressing harmful pathways.
Researchers identified Fab antibody fragments that target the IgE Cε2 domain, effectively stripping IgE from mast cells. The most potent Fab clones showed rapid efficacy in cellular assays and in vivo anaphylaxis models, demonstrating potential as a next-generation anti-allergy therapy.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers propose a new conceptual framework for neutrophils, highlighting their dynamic and adaptable nature. The study reveals neutrophils' functional diversification and immunological memory capabilities, opening avenues for innovative therapeutic strategies.
Researchers at Colorado State University used AI to modify antibodies into stable intrabodies that can visualize histone modifications in real-time. This allows for better understanding of gene expression and its relationship with cancer and other disorders. The team created 19 new antibody-based probes with a 70% success rate, signifi...
Researchers developed a new way to stimulate the immune system to attack tumor cells by blocking an immune checkpoint. They created multifunctional molecules called AbLecs, which combine a lectin with a tumor-targeting antibody, and showed they could boost the immune response to cancer cells.
MIT researchers have found a new way to create solid particles of highly concentrated antibodies, suspended in a solution, which can be injected using a standard syringe. This advance could make antibody treatments more convenient and accessible for patients, particularly older people with difficulty visiting hospitals.
Researchers used AI to identify a new viral surface protein that triggers the production of neutralizing antibodies, offering a breakthrough for developing effective vaccines and antibody therapies. The discovery could also provide insights into treating smallpox, a related virus posing a bioterrorism risk.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at UC Santa Barbara propose a cyst-targeted therapy using monoclonal antibodies to interrupt the runaway growth of fluid-filled sacs in polycystic kidney disease. The treatment, targeting a driver of cyst progression, shows promise in slowing or reversing the disease with minimal side effects.
Researchers found that immune cells in the gut follow an atypical pathway to produce antibodies providing long-term protection against viruses. The study could help guide the development of better vaccines for respiratory viruses like influenza and SARS-CoV-2.
Researchers have developed an innovative antibody-based enzyme switch called 'Switchbody', which is activated upon antigen binding. The switch's mechanism relies on a 'trap-and-release' process, offering new opportunities in diagnostics and therapeutics.
In response to rising RSV cases, ECDC advises policymakers and public health authorities on effective ways to mitigate the impact of RSV disease in infants. Immunisation interventions, including long-acting monoclonal antibodies and maternal vaccines, can prevent severe illness and hospitalization.
A 47-year-old man from New Jersey died after consuming beef due to a tick-borne meat allergy caused by the Lone Star tick's alpha-gal sugar. Researchers identified the allergy and its link to fatal anaphylaxis, urging physicians to investigate severe abdominal pain after eating red meat in areas with high Lone Star tick populations.
Researchers at the University of Pittsburgh have developed a skin patch test that can detect antibodies associated with COVID and flu infections. The test uses carbon nanotubes and is orders of magnitude more sensitive than existing tests.
Researchers developed a protein language model that can generate functional antibodies against specific viral antigens. This approach enables rapid generation of antibodies against emerging health threats without requiring blood samples or antigen proteins.
Researchers discover tiny antibody-like proteins from camels and llamas that can treat brain disorders like schizophrenia and Alzheimer’s disease with fewer side effects. The nanobodies are smaller than conventional antibodies, making them easier to produce and purify.
A randomized clinical trial has shown that rituximab is effective in preventing relapses and reducing the need for corticosteroids in adults with relapsing nephrotic syndrome. The study involved 66 adult patients treated with either rituximab or a placebo, with impressive results at the 49-week follow-up.
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
Researchers developed a new approach to overcome treatment resistance in aggressive cancers by activating macrophages, a type of immune cell abundant in advanced tumors. The custom anti-αvβ3 antibody triggers powerful anti-tumor responses and is highly selective, making it a potentially safer alternative.
A newly identified antibody, 04_A06, has been found to block 98.5% of over 300 different HIV strains in laboratory tests. In humanized mice models, the antibody reduced viral load to undetectable levels, offering a promising approach for HIV prevention and treatment.
A team of international researchers, led by UC Riverside's Scott Pegan, are developing protective antibodies against CCHFV using monoclonal antibody treatments and exploring non-traditional viral targets. The study aims to identify life-saving therapeutics for future nairovirus outbreaks.
A study comparing immunoblot assays and ELISA for detecting anti-F-actin antibodies in autoimmune hepatitis type 1 reveals comparable accuracy, with immunoblotting providing higher specificity. The findings suggest that immunoblot assays could be a reliable alternative to ELISA for diagnostic purposes, but larger studies are needed.
A Japanese study has identified four distinct patterns of immune response after COVID-19 vaccines, with a 'rapid-decliner' group experiencing faster decline in antibody levels. Monitoring changes in antibody levels may help identify individuals at greater risk of infection and inform more effective vaccination strategies.
Researchers have found a way to use antibodies to direct T cells to kill Cytomegalovirus-infected cells, offering an alternative treatment for life-threatening infections without expensive and side-effect-prone drugs.
Researchers at UMass Amherst found that certain T-cells have an inherent ability to remember past viral foes, which could lead to next-generation cancer vaccines. This 'immunological memory' is crucial for the body's immune response and can be harnessed for targeted therapies.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Researchers found that a high fiber diet reduced Alzheimer's-related frailty and tremor in mice by restoring balance in the gut immune system. This discovery provides a potential new therapeutic pathway for the disease.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
A team of researchers at Mount Sinai discovered three powerful monoclonal antibodies that target the viral protein A35 and block viral spread in laboratory tests. These antibodies also protected rodents from severe disease and fully prevented death, suggesting they could be promising drug candidates for mpox treatment.
Researchers developed a new method to identify functional plasma antibodies against malaria using mass spectrometry sequencing, providing valuable insight into protective antibody responses. The study identified a broadly neutralizing antibody with broad inhibitory activity against diverse PfEMP1 variants.
The R21/Matrix-M malaria vaccine generates nearly identical antibodies to those following a natural infection, providing strong protection against the earliest life stage of malaria parasites. This long-lasting immunity is effective without requiring further adaptation.
Researchers discovered how glycosylation modulates IgG antibody architecture, enabling precision immunotherapies for cancer and autoimmune diseases. The study's findings highlight the power of integrating experimental and computational approaches to decode glycoprotein dynamics and optimize clinical performance.
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
A study published in Nature found that autoantibodies can tilt the odds dramatically toward shrinking tumors and enhance the effectiveness of immunotherapy. Certain autoantibodies linked to better clinical outcomes could reveal cancer's weak spots and point to new targets for treatment.
Scientists have designed a nanobody made from llama antibodies to activate a glutamate receptor involved in neural activity, improving cognitive function in mouse models of schizophrenia. Peripheral administration has shown promise as a new therapeutic strategy for treating the condition.
Researchers discovered a new monoclonal antibody, 2B010, that selectively targets regulatory T cells (Tregs) in tumors, boosting the activity of CD8+ T cells and improving anti-tumor immune responses. This unique mechanism could complement existing cancer therapies and lead to more effective treatments.
Researchers at Scripps Research Institute have developed a new microchip that can reveal how antibodies interact with viruses, allowing for faster and clearer insights into vaccine development. The technology offers a quicker-than-ever method to analyze antibody interactions, enabling scientists to design more effective vaccines.
Researchers at University of Queensland have discovered a nanobody to combat two highly lethal viruses with no approved vaccine or cure. The DS90 nanobody can access hard-to-reach areas of the virus to block infection.
Researchers are creating a single-cell atlas to identify potent antibody therapies against measles, mumps, and rubella viruses. The goal is to accelerate antibody discovery and inform vaccine design.
Deepshika Ramanan, a Salk Assistant Professor, has been recognized as a Rita Allen Foundation Scholar for her innovative research on maternal immunity and lactation. She will receive annual grants of up to $110,000 to conduct groundbreaking work in neuroscience, cancer, immunology, and pain.
Researchers at Mass General Hospital discovered that humans are born with a genetic predisposition to develop IgG antibodies to peanut proteins. These findings have significant implications for the treatment and prevention of food allergies.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers identified specific antibody features that limit Mtb growth, revealing critical insights into antibody-immune cell interactions. The study lays groundwork for potential antibody-based therapies or vaccines against tuberculosis, an urgently needed treatment for the deadly infectious disease.